Zoom In on Dementia & Alzheimer's Episodes
Listen to world-renowned Alzheimer’s expert Dr. Marwan Sabbagh as he guides us through the complex stages and progression of Alzheimer’s and helps us understand the resources available at each stage.
In 2023, there were 184 trials assessing 143 drugs for the treatment of Alzheimer's disease (AD) and Mild Cognitive Impairment, with more than 60,000 participants required to populate those registered trials at 5684 sites. What is happening in 2024? Listen to Dr. Jeffrey Cummings for the insider’s overview.
Three new drugs for Alzheimer’s disease have been approved, and pharmaceutical companies are currently testing 141 Alzheimer’s drugs in 178 clinical trials. World-renowned expert Dr. Reisa Sperling discusses what might be coming through the treatment pipeline for dementias within the next three years.
Join Dr. Richard S. Isaacson as he shares insights on how preventative lifestyle changes and individualized care can meaningfully reduce your dementia risk and benefit your overall health.
From written evaluations to blood tests, retinal and brain scans, AI-based wearable technologies, and everything in between, Dr. Randall J. Bateman takes a deep dive into the latest and greatest methods that can lead to earlier detection of dementias.
New treatments and diagnostic tests for Alzheimer’s disease and other dementias are making headlines, with more approvals of medications expected this summer and many others in the pipeline. Join Dr. Cynthia Lemere, Scientist at Brigham and Women’s Hospital and Associate Professor of Neurology at Harvard Medical School, and host Nancy Lynn of BrightFocus Foundation for a discussion on the rapidly evolving—and complex—landscape of available treatments for Alzheimer’s disease and ask the experts what this means for you or a family member.
Learn about the role that genes play in the risk of developing the early- and late-onset forms of Alzheimer’s disease. Dr. John Hardy, chair of molecular biology of neurological disease at University College London Institute of Neurology, and host Nancy Lynn discuss the impact of family history on Alzheimer’s disease.
Learn about frontotemporal dementia (FTD), a form of dementia, and how it differs from Alzheimer’s disease. Dr. Malú Gámez Tansey, professor of neuroscience and neurology at the University of Florida, and host Nancy Lynn discuss the signs, symptoms, and stages of FTD.
The premier episode of Zoom in on Dementia & Alzheimer's focused on Leqembi, a new anti-amyloid treatment for Alzheimer's disease that received conditional approval from the FDA in January 2023.
